Ibrahim Aldoss, MD

Ibrahim Aldoss, MD, is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope

Articles

Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

March 20th 2025

Drs Aldoss and Jabbour discuss an analysis of PhALLCON that support the use of ponatinib monotherapy after TKI/chemotherapy treatment in Ph-positive ALL.

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Current Standards of Care for Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss current standards of care for the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Prevalence and Prognosis of Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr Aldoss on Responses With WU-CART-007 After Enhanced Lymphodepletion in R/R T-ALL/LBL

June 14th 2024

Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.

Dr Aldoss on the Utility of Ponatinib in Ph+ ALL

May 6th 2024

Ibrahim Aldoss, MD, discusses the utility of ponatinib in the phase 3 PhALLCON trial for patients with newly diagnosed, Ph+ acute lymphoblastic leukemia.

Dr Aldoss on the Mechanism of Action of Ponatinib in Ph+ ALL

April 29th 2024

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.

Dr Aldoss on the Use of Revumenib in KMT2A-Rearranged Acute Leukemia

January 26th 2024

Ibrahim T. Aldoss, MD, discusses the use of revumenib monotherapy in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements.

Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALL

July 12th 2023

With their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.

Notable Advancements in Treatment for ALL

July 12th 2023

Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.

Ponatinib and Blinatumomab Use in Patients with Newly Diagnosed Ph+ ALL

July 5th 2023

Dr Aldoss discusses the role ponatinib and blinatumomab in the management of Ph+ALL.

Recent Updates from the PhALLCON Study

July 5th 2023

Medical experts highlight recent findings from the PhALLCON study.

Evolving Standard of Care for Patients Diagnosed with Ph+ ALL

June 28th 2023

Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.

Defining and Diagnosing Philadelphia Chromosome-Positive (Ph+) ALL

June 28th 2023

Amanda Przespolewski, DO, and Ibrahim Aldoss, MD define and discuss how to diagnose patients with Ph+ALL.

Sequencing Therapies in Relapsed/Refractory ALL

August 24th 2021

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share thoughts on how to effectively sequence available treatment modalities for acute lymphocytic leukemia in various patient populations.

Salvage Therapies in R/R ALL, Including CAR T-Cell Therapy

August 24th 2021

Drs Aldoss and McKloskey describe treatments that can be used in the salvage setting of acute lymphocytic leukemia, including CAR T-cell therapy.

Approaches to Treatment for Relapsed/Refractory ALL

August 17th 2021

Ibrahim Aldoss, MD and James K. McCloskey, MD describe treatment modalities that can be utilized in treating a pediatric or AYA patient with relapsed / refractory ALL.